Abstract
EVIDENCE-BASED ANSWER The effect of osteoporosis screening in postmenopausal women is unclear. In a mixed population of pre- and postmenopausal women, osteoporosis screening increases the use of medications to treat osteoporosis and slightly decreases all fractures by an absolute difference of 0.6%, but does not decrease osteoporotic fractures of the hip, lumbar spine, femur, or wrist (SOR: B, RCT). In a mixed male and female population 65 years of age and older, screening is associated with 3.4 fewer hip fractures per 1,000 patients (SOR: B, cohort trial). Screening for osteoporosis is recommended in women 65 years and older, and younger women with similar risk to a white woman 65 years of age without other risk factors (SOR: B, evidence-informed guidelines).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
